Navigation Links
Rheumatoid Arthritis: World Drug Market 2011-2021
Date:11/2/2011

r Rheumatoid Arthritis, 2011

6.2.1 Lodotra (Horizon; SkyePharma)

6.3 R&D Pipeline: Biologics to Treat Rheumatoid Arthritis, 2011

6.3.1 Denosumab (Amgen)

6.3.2 Fostamatinib (AstraZeneca)

6.3.3 Tofacitinib (Pfizer)

6.3.4 Ofatumumab (Genmab; GSK)

6.3.5 Masitinib (AB Science)

6.3.6 Belimumab (GSK; Human Genome Sciences)

6.3.7 Canakinumab (Novartis)

6.3.8 Baminercept Alfa (Biogen Idec)

6.3.9 Ocrelizumab (Roche)

6.3.10 Sarilumab (Regeneron; Sanofi)

6.3.11 dnaJP1 (Adeona)

6.3.12 T-5224 (Roche; Toyoma Chemicals)

6.3.13 Anti- BAFF Monoclonal Antibody (Eli Lilly)

6.3.14 Olokizumab (UCB)

6.3.15 Anti-IL-17 Monoclonal Antibody (Eli Lilly)

6.3.16 JAK1/JAK2 Inhibitor (Eli Lilly)

6.3.17 Sirukumab (Johnson and Johnson)

6.3.18 INCB018424 (Incyte Corporation)

6.3.19 ALD 518 (Bristol Myers Squibb; Alder Biopharmaceuticals)

6.3.20 GSK3152314A (GlaxoSmithKline)

6.3.21 RPI-MN (ReceptoPharm)

6.3.22 MT203 (Nycomed)

7. Leading National Markets for Rheumatoid Arthritis Treatments, 2011-2021

7.1 Leading National Markets for Rheumatoid Arthritis, 2010-2021

7.2 The US Rheumatoid Arthritis Market, 2011-2021

7.3 The Japanese Rheumatoid Arthritis Market, 2011-2021

7.4 The Leading European Markets for Rheumatoid Arthritis Treatments, 2011-2021

7.5 Rheumatoid Arthritis Drug Market in Emerging Economies, 2011-2021

7.5.1 The Chinese Rheumatoid Arthritis Market, 2011-2021

7.5.2 The Indian Rheumatoid Arthritis Market, 2011-2021

7.6 Rheumatoid Arthritis Treatments in the Rest of the World, 2011-2021

7.7 Summary of National Market Forecasts

8. Leading Companies in the Rheumatoid Arthritis Drug Market, 2011

8.1 Introduction

8.2 Roche

8.3 Abbott Laboratories

8.4 Amgen

8.5 Johnson & Johnson

8.6 Biogen Ide
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Positive Phase 2b Results with Sarilumab in Rheumatoid Arthritis to be Presented as a Late-Breaking Poster at the 2011 American College of Rheumatology Annual Meeting
2. Rheumatoid Arthritis Market Forecast
3. HYCOR Broadens Diagnostic Offerings, Announces Agreements to License Biomarkers for Celiac Disease and Rheumatoid Arthritis
4. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
5. Alder Biopharmaceuticals to Receive $15 Million Milestone Payment from Bristol-Myers Squibb for Initiation of Phase 2b Clinical Trial in Rheumatoid Arthritis of ALD518/BMS-945429 Antibody Therapeutic Against IL-6
6. Approved Biologic Therapies in Rheumatoid Arthritis Show Further Evidence of Efficacy and Reduction in Joint Damage at the 2011 European League Against Rheumatisms Congress
7. Exagen Diagnostics Inc. Partners with Medco Research Institute® to Develop NIMBLE Personalized Medicine Program for Rheumatoid Arthritis Patients
8. Cimzia® (certolizumab pegol) Data Showed Rapid Improvement in Signs and Symptoms Predicted Better Long-Term Outcomes in Rheumatoid Arthritis Patients
9. Cimzia® (certolizumab pegol) Data Showed Broad and Rapid Relief From Burden of Symptoms In Rheumatoid Arthritis Patients
10. Reportlinker Adds U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
11. Reportlinker Adds Epidemiology: Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/15/2014)... FRANKLIN, Ohio , Jan. 15, 2014  A novel wearable ... it easy and painless for patients to self-inject prescription drugs ... of disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... expected to grow to $220B by 2018, according to analysts.   ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2
... , SWARTZ CREEK, Mich., Nov. 17 Diplomat Specialty ... Bernardino, CA . Diplomat has 6 additional locations in ... contracts with managed care organizations in California will potentially impact ... Managed Care. "Our new San Bernardino location is an important ...
... , SOUTH SAN FRANCISCO, Calif., Nov. 17 ... announced updated clinical data from its randomized, controlled Phase ... cancer (CRC). The updated results indicated that picoplatin, ... and leucovorin in the FOLPI regimen, has comparable efficacy ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Continues to Expand - Opens Location in Southern California 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 2Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 3Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 4Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results 5
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... first genetic variant specifically associated with the risk ... 10-15 per cent of all breast cancer cases. ... cancer sub-type, called invasive lobular carcinoma, gives researchers ... particular kind of breast cancer, which can be ... (Thursday) in the journal PloS Genetics , ...
(Date:4/17/2014)... PLOS Pathogens , children who live in regions of ... immune response to infection with malaria parasites that may ... and illness and partially control the growth of malaria ... develop future interventions that prevent or mitigate the disease ... 200 million cases of malaria occur worldwide, resulting in ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2Health News:CU researchers discover target for treating dengue fever 2
... investigational device that specifically targets rapidly growing cancer cells ... (TTFields), has found that it more than doubled the ... common and aggressive type of malignant brain tumor. ... to disrupt tumor growth by interfering with cell division ...
... survey of DNA samples from nearly 50,000 women, half of ... mutation that holds 60 per cent increased risk of breast ... of Cambridge says that the gene mutation was observed in ... ,The researchers say that the newly identified gene variant, in ...
... has announced a 90 percent reduction in the price of ... rising number of deaths caused by them. ... 3,500 "people's pharmacies," where the government offers subsidized medicines. ... Catholic Church and Lula's government over abortion. ,During ...
... Pharmaceuticals Inc. has received final approval from the U.S. ... Abbreviated New Drug Application (ANDA) for Fluoxetine Capsules USP, ... version of Eli Lilly and Company's Prozac(R) Capsules. Fluoxetine ... the 12 months ending March 31, 2007, for the ...
... high staffing standards for elder care in nursing homes are ... nurses to prevent serious safety violations, according to a ... Nursing. ,The majority of the nation's elderly and ... well below national recommendations for safe care, the study found. ...
... analysing climate simulations we can see there are changes in ... variability',said CSIRO oceanographer Dr Gael Alory. ,'These ... heat structure of the atmosphere and have led to a ... around two degrees celsius. ,'At the same time, ...
Cached Medicine News:Health News:Device That Targets Brain Cancer Shows Promising Results 2Health News:Researchers Identify the Gene Mutation That Raises Breast Cancer Risk 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 2Health News:Policy Changes Have Direct Effect on Nursing Home Care 3Health News:Climate Change Signal Detected in the Indian Ocean 2
Inquire...
... A fast, reliable and accurate immunoassay ... and plasma. , ,The fully automated Elecsys ... failure in symptomatic patients. NT-proBNP levels also ... allow the assessment of prognosis. In addition, ...
... there is a more efficient way ... fully portable battery operated patient warming ... surgical teams with a compact and ... the entire surgical process. Its unique ...
... system consists of our compact and ... blankets for use with patients of ... Blankets are available for intra and ... sizes and a sterile cardiac blanket ...
Medicine Products: